Effect of Inulin Supplementation on Glycaemic Control and Immunological Parameters in Type 1 Diabetes (2024)

Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Jul 2, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether taking a supplement called inulin can help adults with type 1 diabetes better manage their blood sugar levels and support their immune system. Inulin is a type of fiber found in some plants that may also affect the bacteria living in the gut, which could play a role in diabetes. The study will compare people who take inulin to those who take a placebo (a “dummy” supplement) to see if there are any differences in continuous blood sugar monitoring and immune health.

Adults with type 1 diabetes who have had blood sugar levels outside the target range (less than 80% of the time in range) in the past month may be eligible to join. People currently taking fiber supplements, recent antibiotic users, or those with certain health conditions like active infections or bowel problems won’t be able to participate. If you join, you’ll take either inulin or a placebo without knowing which one you have, and the researchers will regularly check your blood sugar, immune markers, and gut health. The study aims to better understand if inulin can be a helpful addition to managing type 1 diabetes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • A diagnosis of type 1 diabetes, as made by their primary clinician
• • A time in range of \<80% in the last four weeks before screening
• Exclusion Criteria:
• • Use of any fibre supplementation (within the last month before screening or ongoing)
• • Use of antibiotics in the lasts three months before screening or during study period
• • Active infection during the study visit
• • Inability or unwillingness to donate feces or urine.
• • Illicit drug use (e.g. MDMA/amphetamine/cocaine/heroin/GHB) in the past three months or use during the study period.
• • Inability or unwillingness to provide informed consent.
• • Absence of a large bowel (ie colostomy)
• • Active inflammatory bowel disease